Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature

Abstract

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (AT II) receptor blockers (ARBs) are widely used antihypertensives with well-recognized renoprotective and cardioprotective effects. Although treatment with these agents generally does not result in adverse metabolic consequences, their use during human pregnancy has been associated with negative reactions. Here we report a premature baby with a history of oligohydramnios and maternal exposure to the ARB olmesartan medoxomil who was transferred to our institution with acute renal failure. Conservative treatment with diuretics and meticulous management of fluids and electrolytes resulted in an improvement in renal function in the patient. We conclude that olmesartan medoxomil may cause reversible renal failure in premature neonates.

DOI: 10.1093/ndtplus/sfp045

Extracted Key Phrases

1 Figure or Table

Cite this paper

@inproceedings{GeorgakiAngelaki2009OlmesartanMA, title={Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature}, author={Eleni Georgaki-Angelaki and Nicolaos Stergiou and Ekaterini Naoum and Ioannis Papassotiriou and Marina Anagnostakou}, booktitle={NDT plus}, year={2009} }